<div style="text-align:justify;"> <strong><span style="font-family:Verdana;">Background:</span></strong><span style="font-family:Verdana;"> Intensity M...<div style="text-align:justify;"> <strong><span style="font-family:Verdana;">Background:</span></strong><span style="font-family:Verdana;"> Intensity Modulated Radiation Therapy (IMRT) is currently employed as a major arm of treatment in multiforme glioblastoma (GBM). The present study aimed to compare 3D-CRT with IMRT to assess tumor volume coverage and OAR sparing for </span><span style="font-family:Verdana;">the </span><span "=""><span style="font-family:Verdana;">treatment of malignant gliomas. </span><b><span style="font-family:Verdana;">Materials</span></b> <b><span style="font-family:Verdana;">and</span></b> <b><span style="font-family:Verdana;">methods:</span></b><span style="font-family:Verdana;"> We assessed 22 anonymized patients datasets with High Grade Glioblastoma who had undergone post</span></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">operative Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3D-CRT), This study will compare and contrast treatment plans Rapidarc and 3D-CRT to determine w</span><span style="font-family:Verdana;">h</span><span style="font-family:Verdana;">ich techn</span><span style="font-family:Verdana;">ology</span><span "=""><span style="font-family:Verdana;"> improves significantly dosimetric parameters. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> Plans will be assessed by reviewing the coverage of the PTV using mean, maximum and minimum doses while the OAR doses will be compared using the maximal doses for each, as set out in the QUANTEC dose limits. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The use of IMRT seems a superior technique as compared to 3D-CRT for the treatment of malignant gliomas having the potential to increase </span></span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">dose to the PTV while sparing OARs optimally.</span> </div>展开更多
Uterine sarcomas are rare malignant tumors characterized by a great clinical and histopathological diversity. The aim of this work is to analyze the difficulties of diagnosis, therapeutic and prognosis posed by these ...Uterine sarcomas are rare malignant tumors characterized by a great clinical and histopathological diversity. The aim of this work is to analyze the difficulties of diagnosis, therapeutic and prognosis posed by these tumors. Thirty-seven patients with uterine sarcoma, collected in the service Radiotherapy and Oncology, University Ibn Rochd of Casablanca between January 2000 and December 2007 were included in this study retrospective. The average patient age was 50 years (17-76). The bleeding was present in all patients, isolated in 54% of cases associated with pelvic pain in 24.6% and a mass abdomino-pelvic in seven patients. The average time of evolution was 10 months. The main histological type was found leiomyosarcoma. Twenty four patients in our series underwent total hysterectomy without annexial conservation. The surgery R0 was obtained in 43% of cases. The sarcomas were classified as stage IV in 51.4%. Adjuvant radiotherapy was indicated in 13 patients. After a mean of 20 months, half of patients evaluable presented a local relapse and/or metastatic, the third of cases were tumor progression while complete remission was maintained in 18.5% of cases. Uterine sarcomas are rare malignant mesenchymal tumor, which often occur in women after menopause. The main prognostic factors are hormonal status of the patient, stage clinical, histological type, histological grade and quality surgical excision. The management of uterine sarcomas is multidisciplinary, based mainly on surgery remains the only means of cure. Adjuvant radiotherapy allows decreased risk of local recurrence, with no impact on survival achieved at best 30% at 5 years. The role of chemotherapy remains confirm.展开更多
文摘<div style="text-align:justify;"> <strong><span style="font-family:Verdana;">Background:</span></strong><span style="font-family:Verdana;"> Intensity Modulated Radiation Therapy (IMRT) is currently employed as a major arm of treatment in multiforme glioblastoma (GBM). The present study aimed to compare 3D-CRT with IMRT to assess tumor volume coverage and OAR sparing for </span><span style="font-family:Verdana;">the </span><span "=""><span style="font-family:Verdana;">treatment of malignant gliomas. </span><b><span style="font-family:Verdana;">Materials</span></b> <b><span style="font-family:Verdana;">and</span></b> <b><span style="font-family:Verdana;">methods:</span></b><span style="font-family:Verdana;"> We assessed 22 anonymized patients datasets with High Grade Glioblastoma who had undergone post</span></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">operative Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3D-CRT), This study will compare and contrast treatment plans Rapidarc and 3D-CRT to determine w</span><span style="font-family:Verdana;">h</span><span style="font-family:Verdana;">ich techn</span><span style="font-family:Verdana;">ology</span><span "=""><span style="font-family:Verdana;"> improves significantly dosimetric parameters. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> Plans will be assessed by reviewing the coverage of the PTV using mean, maximum and minimum doses while the OAR doses will be compared using the maximal doses for each, as set out in the QUANTEC dose limits. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The use of IMRT seems a superior technique as compared to 3D-CRT for the treatment of malignant gliomas having the potential to increase </span></span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">dose to the PTV while sparing OARs optimally.</span> </div>
文摘Uterine sarcomas are rare malignant tumors characterized by a great clinical and histopathological diversity. The aim of this work is to analyze the difficulties of diagnosis, therapeutic and prognosis posed by these tumors. Thirty-seven patients with uterine sarcoma, collected in the service Radiotherapy and Oncology, University Ibn Rochd of Casablanca between January 2000 and December 2007 were included in this study retrospective. The average patient age was 50 years (17-76). The bleeding was present in all patients, isolated in 54% of cases associated with pelvic pain in 24.6% and a mass abdomino-pelvic in seven patients. The average time of evolution was 10 months. The main histological type was found leiomyosarcoma. Twenty four patients in our series underwent total hysterectomy without annexial conservation. The surgery R0 was obtained in 43% of cases. The sarcomas were classified as stage IV in 51.4%. Adjuvant radiotherapy was indicated in 13 patients. After a mean of 20 months, half of patients evaluable presented a local relapse and/or metastatic, the third of cases were tumor progression while complete remission was maintained in 18.5% of cases. Uterine sarcomas are rare malignant mesenchymal tumor, which often occur in women after menopause. The main prognostic factors are hormonal status of the patient, stage clinical, histological type, histological grade and quality surgical excision. The management of uterine sarcomas is multidisciplinary, based mainly on surgery remains the only means of cure. Adjuvant radiotherapy allows decreased risk of local recurrence, with no impact on survival achieved at best 30% at 5 years. The role of chemotherapy remains confirm.